eyonis® LCS

by Median Technologies  · Based in United States → — Catching the unseen.
Oncology Pulmonology Radiology

Regulatory Status Disclosed

Overview

Median Technologies is a pioneer in applying artificial intelligence technologies to medical imaging, developing and marketing eyonis®, a suite of AI-powered Software as a Medical Device (SaMD) for the early diagnosis of solid tumor cancers. eyonis® LCS is specifically designed for lung cancer screening procedures. The company’s mission is to shift the imaging diagnostic paradigm by designing innovative AI/ML tech-based SaMDs, supporting radiologists and healthcare professionals worldwide in screening, early diagnosis, and treatment of cancer. Their vision is to establish eyonis® as a Standard-of-Care (SoC) to reduce the cancer burden by helping identify disease at the earliest stage, allowing better care while avoiding unnecessary medical procedures and reducing healthcare costs. Median Technologies also provides central imaging services and AI-based image analysis for oncology clinical trials in the biopharmaceutical industry through its iCRO business.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI/ML-powered computer-aided detection and diagnosis (CADe/CADx)
  • Early detection, localization & diagnosis of solid & part solid pulmonary parenchymal nodules (4-30 mm Longest Average Diameter) on Chest Low-Dose Computed Tomography (LDCT) images.
  • Generates DICOM file result reports, PACS available & compatible with every radiologist's viewer.
  • Lists all probably benign, suspicious, very suspicious lung nodules present in LDCT image series.
  • Scores nodules individually by giving a malignancy score & providing a Likelihood of Malignancy (LOM%) from 1% to 93%.
  • 93.3% sensitivity in detecting cancer cases.
  • 92.4% specificity in identifying benign cases.
  • 99.9% Negative Predictive Value (NPV).
  • 66% False Negative reduction.
  • 68% False Positive reduction.

Use Cases

  • Lung cancer screening programs.
  • Aiding radiologists in detecting and characterizing parenchymal pulmonary nodules.
  • Supporting clinical decision-making and patient follow-ups.
  • Reducing inter-reader variability in lung cancer screening.
  • Improving the efficiency and consistency of lung cancer screening programs.

Details

Category Oncology AI
Pricing Unknown
DeploymentCloud-based or institution local hosting. DICOM images are collected via the eyonis® Gateway & sent to the eyonis® Cloud for processing. The final result report is then PACS available.
Compliance
BAA AvailableUnknown
HIPAA CompliantUnknown
FDA Status Cleared AI-estimated
Integrations
EHR Not specified
Specialties Oncology, Pulmonology, Radiology

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate eyonis® LCS

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money
No press coverage or publications on file yet. Know of some? Suggest an edit →

Videos

Product demos, reviews, and walkthroughs for eyonis® LCS.

View all on YouTube

Frequently Asked Questions

eyonisu00ae LCS is an AI/ML-powered Software as a Medical Device (SaMD) designed to assist clinicians in detecting and characterizing lung parenchymal nodules on low-dose CT (LDCT) scans. It aims to improve diagnostic accuracy by reducing both false positives and false negatives, thereby supporting earlier cancer diagnosis, patient risk stratification, and improved clinical management.
eyonisu00ae LCS received FDA 510(k) clearance in February 2026 for commercialization in the U.S. market. It also obtained CE marking as a Class IIb medical device under the new European Medical Device Regulation (MDR 2017/745) in July 2026, enabling its commercial launch across the European Economic Area.
eyonisu00ae LCS has demonstrated superior performance compared to traditional lung cancer screening by unaided radiologists, with 93.3% sensitivity and 92.4% specificity, versus 80.3% sensitivity and 76.4% specificity for traditional methods. It is also noted as the first AI-based solution to combine computer-aided detection (CADe) and computer-aided diagnosis (CADx) directly within the LDCT lung cancer screening pathway.
While eyonisu00ae LCS significantly improves diagnostic accuracy and efficiency, it's important to remember that AI in screening aids radiologists and does not eliminate the need for human interpretation. The successful integration into existing clinical workflows and the ongoing training of healthcare professionals will be crucial for its optimal use.
In the U.S., eyonisu00ae LCS is reimbursable under the New Technology Ambulatory Payment Classification (NT-APC) pathway. For 2026, the Medicare Outpatient Prospective Payment System (OPPS) is expected to pay approximately $601-$700 per exam, providing a predictable payment pathway for providers. Median Technologies estimates the annual total addressable market for lung cancer screening in the U.S. exceeds $9 billion, driven by approximately 14.5 million eligible individuals.
eyonisu00ae LCS is engineered for flexible and seamless deployment and can be directly integrated into hospital Picture Archiving and Communication Systems (PACS). This integration aims to enhance diagnostic accuracy and reduce routine workload for clinicians.
The efficacy and safety of eyonisu00ae LCS have been evaluated in two pivotal studies, REALITY and RELIVE, which were successfully completed and used for regulatory submissions in the U.S. and Europe. Manufacturer values demonstrated 93.3% sensitivity and 92.4% specificity, along with a 99.9% negative predictive value, indicating a very low rate of false positives.

Related Tools

VERITON CT 400 Series Digital SPECT/CT System (VERITON CT 416/464)
Spectrum Dynamics Medical
Oncology AI
The VERITON CT 400 Series is a digital SPECT/CT system with a 360-degree gantry and 12 swiveling CZT detectors, offering high sensitivity and quantitative accuracy for a wide range of nuclear medicine applications, including advanced theranostics imaging.
syngo.via MI Workflows, syngo MBF
Siemens Medical Solutions USA
Cardiology AI
syngo.via MI Workflows, syngo MBF is an intelligent, integrated imaging software that helps address the challenges of interpreting, managing, and sharing complex data from molecular imaging scanners, providing automated workflows and advanced visualization for various clinical applications.
syngo.via MI WorkFlows, Scenium, syngo MBF
Siemens Medical Solutions USA
Cardiology AI
syngo.via MI Workflows, Scenium, and syngo MBF are medical diagnostic post-processing applications for viewing, manipulation, quantification, analysis, and comparison of PET or nuclear-medicine functional data with CT or MR anatomical data across timepoints, supporting disease management and radiotherapy treatment planning by trained healthcare professionals.
BIOGRAPH One
Siemens Healthineers AG
Oncology AI
BIOGRAPH One is a second-generation PET/MR scanner designed to transform PET/MR image quality for a new era, combining high PET precision with powerful MR performance. It enables simultaneous visualization of organ location, function, and cellular metabolism, offering faster image acquisition times and more efficient workflows than previous generations of PET/MR scanners.
Claire™ OCT System
Perimeter Medical Imaging AI
Oncology AI
Perimeter Medical Imaging AI is a medical technology company driven to transform cancer surgery with ultra-high resolution, real-time, advanced imaging tools that address unmet medical needs.S. for intraoperative breast cancer margin assessment.
syngo.via RT Image Suite VC10
Varian Medical Systems, Inc.
Clinical Decision Support & Reference
syngo.via RT Image Suite VC10 offers advanced imaging and workflow solutions for precise and efficient radiation therapy planning.

See all Oncology AI tools →

More from Median Technologies

Median LCS (internal name) / eyonis LCS (trade name) (1.0)
Median Technologies
Clinical Decision Support & Reference
eyonis LCS is an AI/ML-powered Software as a Medical Device (SaMD) for early cancer diagnosis, specifically designed for lung cancer screening. It assists clinicians in detecting and characterizing lung nodules on low-dose CT scans, aiming to improve diagnostic accuracy and reduce false positives and negatives.

View company profile →

Suggest an Edit → | Report an issue | Last Verified: 2026-09-09 | First Added: 2026-09-09
AI Tool Finder
AI-powered search. Results may not be comprehensive.